Detection of HSV-2-specific neutralization antibody titers https://www.selleckchem.com/products/pnd-1186-vs-4718.html Blood was obtained from the saphenous veins and neutralization antibody titers were determined in the presence of complement as described previously [28, 30]. Clinical observations After challenge with wild-type HSV-2 strain MS, the animals were monitored daily until day 60. The number of lesions were counted and the progress of disease was scored using a modified method [31]: 0

= no disease; 1 = redness or swelling; 2 = a few small vesicles; 3 = several large vesicles; 4 = several large ulcers with maceration; 5 = paralysis; and 6 = death. Assay of acute and recurrent vaginal shedding of challenge virus After challenge with wild-type HSV-2 strain AZD0530 ic50 MS, vaginal mucosae were swabbed with a moist calcium alginate swab (Fisher Scientific, Waltham, MA) on days 1, 2, 3, 5, 7 and 9. From days 30 to 60 post challenge swabs were taken daily. Swabs were kept in 1 ml DMEM and stored

at -80°C until assayed for infectious virus by standard plaque assay on Vero cell monolayers. Quantitative real-time PCR At day 60 after intravaginal challenge with HSV-2 strain MS, 12 lower lumbar and sacral dorsal root ganglia were Tanespimycin cell line collected from each of the surviving guinea pigs. Dorsal root ganglia were kept separately in 0.5 ml of normal growth medium and stored at -80°C for further processing. DNA was isolated from each dorsal root ganglion and assayed for viral DNA by quantitative real-time PCR as described previously [27]. Statistical analysis For statistical analysis unpaired Student’s t-tests were performed. Acknowledgements This work was supported by Public Health Service Grant 5RO1AI05088 from the National Institutes of Health. References 1. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM: Herpes simplex virus type 2: epidemiology

and management options in developing countries. Sex Transm Infect 2007,83(1):16–22.PubMedCrossRef 2. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. why Jama 2006,296(8):964–973.PubMedCrossRef 3. Whitley RJ: Herpes simplex encephalitis: adolescents and adults. Antiviral Res 2006,71(2–3):141–148.PubMedCrossRef 4. Lafferty WE, Downey L, Celum C, Wald A: Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000,181(4):1454–1457.PubMedCrossRef 5. Jin F, Prestage GP, Mao L, Kippax SC, Pell CM, Donovan B, Templeton DJ, Taylor J, Mindel A, Kaldor JM, et al.: Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis 2006,194(5):561–570.PubMedCrossRef 6. Roberts CM, Pfister JR, Spear SJ: Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003,30(10):797–800.PubMedCrossRef 7.